$KRRO News

Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Korro Bio, Inc. (KRRO) Upgraded to Buy: What Does It Mean for the Stock?

Korro Bio, Inc. (KRRO) Soars 17.6%: Is Further Upside Left in the Stock?

Korro Bio: RNA Editor Plots Way Back After AATD Study Fail - I'm Holding

One Korro Bio Insider Raised Stake By 19% In Previous Year

Korro to Present at the 2026 Jefferies Global Healthcare Conference

Korro Selects KRRO-111 as Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Korro Bio Announces Addition Of KRRO-111 For Potential Treatment Of AATD To Pipeline Of Therapeutic Programs In Development

HC Wainwright & Co. Maintains Buy on Korro Bio, Lowers Price Target to $15

Citigroup Initiates Coverage On Korro Bio with Buy Rating, Announces Price Target of $21

Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Korro Reports First Quarter 2026 Financial Results and Provides Corporate Update

Korro Bio Q1 EPS $(1.69) Beats $(2.17) Estimate

Korro to Participate in Upcoming Investor Conferences

What Makes Korro Bio, Inc. (KRRO) a New Buy Stock

Korro Bio Presents Oral, Poster Presentations Of Data From Its Oligonucleotide Delivery Based RNA Editing Technology

Korro Bio shares are trading higher after the company reported better-than-expected Q4 sales results. Also, Raymind James upgraded the stock from Market Perform to Outperform and announced a $23 price target.

Korro Bio shares are trading higher after the company reported better-than-expected Q4 sales results. Also, Raymind James upgraded the stock from Market Perform to Outperform and announced a $23 price target.

Cantor Fitzgerald Maintains Overweight on Korro Bio, Raises Price Target to $22

Raymond James Upgrades Korro Bio to Outperform, Announces $23 Price Target